Stock Analysis
- Australia
- /
- Personal Products
- /
- ASX:BXN
Bioxyne Full Year 2024 Earnings: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)
Bioxyne (ASX:BXN) Full Year 2024 Results
Key Financial Results
- Revenue: AU$9.64m (up 82% from FY 2023).
- Net loss: AU$12.8m (loss widened by AU$10.9m from FY 2023).
- AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Bioxyne shares are down 7.1% from a week ago.
Risk Analysis
Be aware that Bioxyne is showing 5 warning signs in our investment analysis and 3 of those can't be ignored...
Valuation is complex, but we're here to simplify it.
Discover if Bioxyne might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:BXN
Bioxyne
A life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia.